Stem Cell Umbilical Cord Blood Market : Global Opportunity Analysis and Industry Forecast, 20202027
- Published Date: 2020-11-26
- Report ID: 21654
- Pages: 209
-
Format:
The global stem cell umbilical cord blood market was valued at $3,110.8 million in 2019, and is projected to reach $10,135.20 million by 2027, registering a CAGR of 16.9% from 2020 to 2027.
Presently, the global stem cell market dominates the healthcare industry with its reliable and cost-effective methods of treatment and fewer side effects. The umbilical cord blood stem cell segment is one of the potential segments of the stem cell market, which is projected to grow in the future. Cord blood is one of the rich sources of stem cells, which are treated as waste after pregnancy or childbirth; however, this blood has huge potential to treat chronic diseases such as cancer, diabetes, and blood disease immune diseases.
Currently, more than 80 genetic diseases can be treated with cord blood and the blood is rich source of hematopoietic stem cells. Various governments are supporting the research and clinical trials of cord blood stem cells, which is has increased the interest of healthcare companies to invest in research and commercialization of cord blood stem cell therapies. However, competition in the market is intense with companies trying to create brand awareness, therefore, compelling market players to adopt many market-based strategies. These stem cells are the only type of cells that are stored in controlled conditions due to their lower volume and higher cell count.
Cost structure of the stem cell treatment has a major impact on the growth of the market in developed countries. Stem cells collected from cord blood are used in treatment of many rare diseases that include metabolic diseases and immune diseases. The overall stem cell umbilical cord blood market is growing from clinical applications to commercialization. Companies involved in the research and commercialization of stem cell therapies are adopting approval and clinical trials as their primary strategy and product launch as their secondary strategy.
Based on the storage services, the market is segmented into private cord blood banks, public cord blood banks and hybrid cord blood banks. The private cord banks segment was the highest contributor to the market, with $1,537 million in 2019, and is estimated to reach $4,765.90 million by 2027, at a CAGR of 15.3% during the forecast period.
Based on therapeutics, the market is categorized into Cancer, Diabetes, Blood diseases, Immune disorders, Metabolic disorders and other diseases. The diabetes segment was the highest contributor to the market, with $794 million in 2019, and is estimated to reach $2,655.58 million by 2027, at a CAGR of 16.4% during the forecast period.
Based on application, the market is categorized into transplant medicine and regenerative medicine. The regenerative medicine segment was the highest contributor to the market, with $1,854.12 million in 2019, and is estimated to reach $5,878.55 million by 2027, at a CAGR of 15.6% during the forecast period.
The stem cell umbilical cord blood market is more lucrative in North America and European countries. Most patents granted for cord blood were from the U.S. and European authorities. North America shared the largest revenue of $1,353.20 million in 2019, however Asia-Pacific is expected to grow at CAGR of 16.7% CAGR during the forecast period.
The companies offering stem cell umbilical cord blood storage services include Cordlife Group Limited, Cord Blood America, Cryo-Cell International, Medipost, Global Cord Blood Corporation, Americord Registry, and Cordvida.
KEY BENEFITS FOR STAKEHOLDERS
This report entails a detailed quantitative analysis along with the current stem cell umbilical cord blood trends from 2019 to 2027 to identify the prevailing opportunities along with the strategic assessment.
The market forecast is studied from 2020 to 2027.
The market size and estimations are based on a comprehensive analysis of key developments in the industry.
A qualitative analysis based on innovative products facilitates strategic business planning.
The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market.
KEY MARKET SEGMENTS
By Storage services
Public Cord Blood Banks
Private Cord Blood Banks
Hybrid Cord Blood Banks
By Therapeutics
Cancer
Diabetes
Blood Diseases
Immune Disorders
Metabolic Disorders
Other Diseases
By Application
Transplant Medicine
Regenerative Medicine
By Region
North America
o U.S.
o Canada
o Mexico
Europe
o UK
o Germany
o France
o Italy
o Spain
o Rest of Europe
Asia-Pacific
o Japan
o China
o Australia
o India
o Rest of Asia-Pacific
LAMEA
o Brazil
o South Africa
o Saudi Arabia
o Rest of LAMEA
Key players in the market
o Cordlife Group Limited
o Cord Blood America
o Cryo-Cell International
o Medipost
o Americord Registry
o Esperite
o China Cord Blood Corporation
o LifeCell Inetrnational
o ViaCord
o Vita34 AG
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Research methodology
1.3.1.Secondary research
1.3.2.Primary research
1.3.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.1.1.Drivers
3.1.1.1.Diversification of services
3.1.1.2.Genetic testing, fertility, and reproduction assisted services
3.1.1.3.Treatment for chronic diseases
3.1.1.4.Rise in spending capacity and suitable payment plans
3.1.2.Restraints
3.1.2.1.Legal and ethical issues during collection
3.1.2.2.Higher cost of therapies
3.1.2.3.Unavailability of suitable matched donor
3.1.3.Opportunities
3.1.3.1.Advancements in therapeutic applications
3.1.3.2.Rise in funds for public storage
3.1.4.Value chain analysis of stem cell umbilical cord blood market
3.2.Top Player Positioning, 2019
CHAPTER 4:STEM CELL UMBILICAL CORD BLOOD MARKET, BY STORAGE SERIVCES
4.1.Overview
4.1.1.Market size and forecast
4.2.Public Cord Blood Banks
4.2.1.Overview
4.2.2.Key growth trends and opportunities
4.2.3.Market size and forecast
4.2.4.Market analysis, by country
4.3.Private Cord Blood Banks
4.3.1.Overview
4.3.2.Key growth trends and opportunities
4.3.3.Market size and forecast
4.3.4.Market analysis, by country
4.4.Hybrid Cord Blood Banks
4.4.1.Overview
4.4.2.Market size and forecast
4.4.3.Market analysis, by country
CHAPTER 5:STEM CELL UMBILICAL CORD BLOOD MARKET, BY THERAPEUTICS
5.1.Overview
5.1.1.Market size and forecast
5.2.Cancer
5.2.1.Overview
5.2.2.Market size and forecast
5.2.3.Market analysis, by country
5.3.Diabetes
5.3.1.Overview
5.3.2.Market size and forecast
5.3.3.Market analysis, by country
5.4.Blood diseases
5.4.1.Overview
5.4.2.Market size and forecast
5.4.3.Market analysis, by country
5.5.Immune Disorders
5.5.1.Overview
5.5.2.Market size and forecast
5.5.3.Market analysis, by country
5.6.Metabolic Disorders
5.6.1.Overview
5.6.2.Market size and forecast
5.6.3.Market analysis, by country
5.7.Others
5.7.1.Overview
5.7.2.Market size and forecast
5.7.3.Market analysis, by country
CHAPTER 6:STEM CELL UMBILICAL CORD BLOOD MARKET, BY APPLICATION
6.1.Overview
6.1.1.Market size and forecast
6.2.Transplant Medicine
6.2.1.Overview
6.2.2.Market size and forecast
6.2.3.Market analysis, by country
6.3.Regenerative Medicine
6.3.1.Overview
6.3.2.Market size and forecast
6.3.3.Market analysis, by country
CHAPTER 7:STEM CELL UMBILICAL CORD BLOOD MARKET, BY REGION
7.1.Overview
7.1.1.Market size and forecast
7.2.North America
7.2.1.Key market trends and opportunities
7.2.2.Market size and forecast, by country
7.2.3.Market size and forecast, by storage service
7.2.4.Market size and forecast, by therapeutics
7.2.5.Market size and forecast, by application
7.2.6.U.S.
7.2.6.1.U.S. market size and forecast, by storage service
7.2.6.2.U.S. market size and forecast, by therapeutics
7.2.6.3.U.S. market size and forecast, by application
7.2.7.Canada
7.2.7.1.Canada market size and forecast, by storage service
7.2.7.2.Canada market size and forecast, by therapeutics
7.2.7.3.Canada market size and forecast, by application
7.2.8.Mexico
7.2.8.1.Mexico market size and forecast, by storage service
7.2.8.2.Mexico market size and forecast, by therapeutics
7.2.8.3.Mexico market size and forecast, by application
7.3.Europe
7.3.1.Europe market size and forecast, by country
7.3.2.Europe market size and forecast, by storage service
7.3.3.Europe market size and forecast, by therapeutics
7.3.4.Europe market size and forecast, by application
7.3.5.UK
7.3.5.1.UK market size and forecast, by storage service
7.3.5.2.UK market size and forecast, by therapeutics
7.3.5.3.UK market size and forecast, by application
7.3.6.France
7.3.6.1.France market size and forecast, by storage service
7.3.6.2.France market size and forecast, by storage service
7.3.6.3.France market size and forecast, by therapeutics
7.3.6.4.France market size and forecast, by application
7.3.7.Germany
7.3.7.1.Germany market size and forecast, by storage service
7.3.7.2.Germany market size and forecast, by therapeutics
7.3.7.3.Germany market size and forecast, by application
7.3.8.Italy
7.3.8.1.Italy market size and forecast, by storage service
7.3.8.2.Italy market size and forecast, by therapeutics
7.3.8.3.Italy market size and forecast, by application
7.3.9.Spain
7.3.9.1.Spain market size and forecast, by storage service
7.3.9.2.Spain market size and forecast, by therapeutics
7.3.9.3.Spain market size and forecast, by application
7.3.10.Rest of Europe
7.3.10.1.Rest of Europe market size and forecast, by storage service
7.3.10.2.Rest of Europe market size and forecast, by therapeutics
7.3.10.3.Rest of Europe market size and forecast, by application
7.4.Asia-Pacific
7.4.1.Key market trends and opportunities
7.4.2.Asia-Pacific market size and forecast, by country
7.4.3.Asia-Pacific market size and forecast, by storage service
7.4.4.Asia-Pacific market size and forecast, by therapeutics
7.4.5.Asia-Pacific market size and forecast, by application
7.4.6.Japan
7.4.6.1.Japan market size and forecast, by storage service
7.4.6.2.Japan market size and forecast, by therapeutics
7.4.6.3.Japan market size and forecast, by application
7.4.7.China
7.4.7.1.China market size and forecast, by storage service
7.4.7.2.China market size and forecast, by therapeutics
7.4.7.3.China market size and forecast, by application
7.4.8.India
7.4.8.1.India market size and forecast, by storage service
7.4.8.2.India market size and forecast, by therapeutics
7.4.8.3.India market size and forecast, by application
7.4.9.Rest of Asia-Pacific
7.4.9.1.Rest of Asia-Pacific market size and forecast, by storage service
7.4.9.2.Rest of Asia-Pacific market size and forecast, by therapeutics
7.4.9.3.Rest of Asia-Pacific market size and forecast, by application
7.5.LAMEA
7.5.1.Key market trends and opportunities
7.5.2.LAMEA market size and forecast, by country
7.5.3.LAMEA market size and forecast, by storage service
7.5.4.LAMEA market size and forecast, by therapeutics
7.5.5.LAMEA market size and forecast, by application
7.5.6.Brazil
7.5.6.1.Brazil market size and forecast, by storage service
7.5.6.2.Brazil market size and forecast, by therapeutics
7.5.6.3.Brazil market size and forecast, by application
7.5.7.South Africa
7.5.7.1.South Africa market size and forecast, by storage service
7.5.7.2.South Africa market size and forecast, by therapeutics
7.5.7.3.South Africa market size and forecast, by application
7.5.8.Saudi Arabia
7.5.8.1.Saudi Arabia market size and forecast, by storage service
7.5.8.2.Saudi Arabia market size and forecast, by therapeutics
7.5.8.3.Saudi Arabia market size and forecast, by application
7.5.9.Rest of LAMEA
7.5.9.1.Rest of LAMEA market size and forecast, by storage service
7.5.9.2.Rest of LAMEA market size and forecast, by therapeutics
7.5.9.3.Rest of LAMEA market size and forecast, by application
CHAPTER 8:COMPANY PROFILES
8.1.Americord Registry LLC
8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.2.China Cord Blood Corporation
8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Business performance
8.3.Cord Blood America, Inc.
8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.4.Cordlife Group Limited
8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance
8.4.6.Key strategic moves and developments
8.5.Cryo-Cell International, Inc.
8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.5.Business performance
8.6.Esperite N.V.
8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.7.LifeCell International Pvt. Ltd.
8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.8.Medipost Co. Ltd.
8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance
8.8.6.Key strategic moves and developments
8.9.ViaCord
8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.10.Vita34 AG
8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
8.10.5.Business performance
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
